News | 09 September 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
The U.S. FDA issued a Form 483 with five observations
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
Subscribe To Our Newsletter & Stay Updated
